ReviewBMC women's health2026
Isolated axillary metastasis from early-stage dMMR endometrial carcinoma: a case report and mini-review.
Review in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionAxillary lymph node metastasis (ALNM) from endometrial carcinoma is extremely rare, particularly in tumors with early-stage, endometrioid histology. The clinical characteristics, underlying mechanisms, and optimal management strategies for this rare metastatic pattern remain insufficiently defined. CASE PRESENTATION: We report a case of a 63-year-old woman diagnosed with FIGO 2023 stage IIB, grade 2 endometrioid endometrial carcinoma exhibiting mismatch repair deficiency (dMMR) and substantial lymphovascular space invasion (LVSI). She underwent surgery followed by adjuvant pelvic radiotherapy and vaginal brachytherapy. Approximately one year later, the patient developed isolated right axillary lymphadenopathy. Histopathological and immunohistochemical analyses confirmed metastatic endometrioid adenocarcinoma of uterine origin. The patient was treated with tislelizumab and lenvatinib but experienced progressive disease, with enlarging axillary nodes and new chest wall involvement. Salvage radiotherapy with a simultaneous integrated boost was administered and achieved tumor regression. A focused review of previously reported cases of axillary lymph node metastasis from endometrial carcinoma was conducted to summarize clinicopathologic features and treatment approaches.
conclusionThis case highlights an unusual metastatic pattern of endometrial cancer and underscores the need for individualized risk stratification, long-term surveillance, and timely integration of local therapy when systemic treatment proves insufficient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.